Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer vaccine injections clear warts that Won't go away?

NCT ID NCT07806617

Disease control Sponsor: Rush University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 16, 2026 · Updated 4 times

Summary

This phase 2 trial tests whether Gardasil-9, a vaccine normally used to prevent HPV infection, can treat warts that have not responded to standard treatments. Researchers inject the vaccine directly into the wart, rather than into a muscle, and compare its effect against a placebo injection. Adults with at least one treatment-resistant wart are randomly assigned to receive either Gardasil-9 or sterile saline, and neither they nor the clinicians know which they get. The study tracks whether the target wart clears and monitors any side effects, along with changes in quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gardasil-9 (9-valent human papillomavirus vaccine) injected directly into the wart
What this could lead to
If it works, this could offer a new treatment for warts that resist standard therapies, potentially clearing them without surgery or harsh chemicals.
What could go wrong
This is an early-phase trial with a small number of participants, so the vaccine may not prove more effective than placebo. Injecting the vaccine into warts could also cause local reactions like pain or swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Immunocompetent (no history of organ transplantation, active malignancy requiring immunosuppressive therapy, or HIV (human immunodeficiency virus) positive status) * At least one wart that has been refractory to treatment * At least two treatment modalities failed, including but not limited to: cryotherapy, electrodesiccation, keratolytic agents, bleomycin, salicylic acid, excision. Exclusion Criteria: * Unable to provide informed consent. * Younger than 18 years of age. * Pregnant. * Prisoner. * Vulnerable populations, including immunocompromised status (active cancer, active tuberculosis (TB) - latent or previous history of these would not exclude patients) * Previous severe reaction to HPV vaccination or known allergy to any vaccine component.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Verruca (warts) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

common wart

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Verruca (warts) Verruca vulgaris Warts

Contacts and locations

Locations

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.